ZYME at a glance
Zymeworks Inc. (ZYME, SEC CIK 1937653) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as July 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Zymeworks Inc. (ZYME) reported revenue of $106.0 million (up 38.9% from FY2024) and a net loss of $81.1 million. Diluted EPS was -$1.08.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Zymeworks Inc. (ZYME) shares worth $385.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $106.0M
- +38.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $385.2M · +0 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 1.01 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: biotechnology company developing multifunctional antibody-based therapeutics for cancer, inflammation, and autoimmune diseases
- New emphasis: commercial launch and milestone revenue focus on Ziihera (zanidatamab-hrii), approved in biliary tract cancer and pending broader regulatory approvals
- Strategic shift: royalty financing via $250M sale of 30% future Ziihera royalties to Royalty Pharma supporting capital and reducing risk
- Key metric: milestone payments received $69.9M in 2025 from partners; potential up to $440M near-term Ziihera milestones from Jazz and BeOne
- Noteworthy fact: use of a special purpose entity to securitize royalties linked to Jazz Collaboration Agreement with a $250M loan maturing in 2042
Risk Factors
- Regulatory risk: BIOSECURE Act may restrict U.S. government contracts to companies using equipment/services from certain Chinese biotech firms, affecting partnerships and operations
- Geopolitical risk: Early-stage clinical supplies sourced from China exposed to ongoing U.S.-China trade tensions and tariffs, risking supply chain disruptions
- Operational risk: Dependence on third-party manufacturers and collaborators; manufacturing difficulties could delay product supply for clinical trials or commercialization
- Competitive risk: Intense competition from better-resourced companies for asset acquisitions may force paying higher prices, reducing potential returns
- Financial risk: Historical losses with only zanidatamab generating royalties; no other product approvals or revenues as of December 31, 2025
Management Discussion & Analysis
- Revenue $106.0M in 2025, up $29.7M (39%) YoY driven by milestone payments from J&J, BeOne, GSK, Daiichi Sankyo, and BMS
- Operating expenses: R&D $137.0M (up 2% YoY), G&A $61.5M (flat YoY); R&D increased due to early-stage programs, zanidatamab R&D down 115% to $(1.8)M
- Best segment: Collaboration revenue milestone growth from multiple partners; worst segment: Zanidatamab R&D costs down $13.7M due to program transition to Jazz
- Cash $270.6M as of Dec 31, 2025; share repurchase $92.5M ($30M completed in 2025, $62.5M through Feb 2026); new $250M loan with Royalty Pharma in March 2026
- Outlook: 2026 focus on Phase 1 trials for ZW191 and ZW251; IND filings for multispecific antibodies on track; Jazz plans zanidatamab sBLA Q1 2026 and potential commercial launch H2 2026
AI summary of the ZYME 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly added Theravance acquisition risk triggered by June 28, 2026 Merger Agreement
- Regulatory risk from HSR Act clearance, with $32.515 million reverse termination fee exposure
- Operational integration risk from retaining Theravance personnel and maintaining partner and supplier relationships
- Financial risk from planned $350 million debt financing, increasing leverage and debt-service obligations
- Market risk from BIOSECURE Act restrictions on biotechnology equipment or services from designated Chinese companies
AI summary of the ZYME 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Material agreement relates to a Note Purchase Agreement and Guaranty and Security Agreement
- Incorporated documents contain the operative financing terms and security provisions for investor review
Item 7.01: Regulation FD Disclosure
- Broad forward-looking disclosure covering merger, financing, milestone payments, royalties, R&D investment, and strategic opportunities
- Investor value depends on successful realization of merger benefits and financing-related flexibility
Item EX-99.1: Item EX-99.1
- Acquisition of Theravance Biopharma completed, making Theravance part of Zymeworks
- Strategic shift toward diversified revenue from commercial assets, royalties, and internal R&D
Item 7.01: Regulation FD Disclosure
- FDA approval expands Ziihera into first-line HER2+ gastroesophageal adenocarcinoma treatment
- Two regimens approved, including combination with Jazz’s Tevimbra and chemotherapy
Item 8.01: Other Events
- FDA approval of two first-line Ziihera regimens in HER2-positive GEA triggers Zymeworks’ $250 million milestone
- Up to $1.3 billion in additional regulatory and commercial milestones remains available
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for the three months ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Zymeworks identifies SEC filings, press releases, investor sites, conferences, and social media as potential sources of material information
- Investors should monitor official company channels beyond 8-K filings for updates on product candidates and corporate matters
Item EX-99.1: Item EX-99.1
- Q2 revenue fell to $4.6M from $48.7M, reflecting absence of prior-year nonrecurring collaboration revenue
- Net loss widened to $45.0M from $2.3M, pressured by lower revenue and $6.6M Royalty Pharma interest expense
AI summaries of ZYME 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ZYME
Don't miss the next ZYME filing
- Alerts as it files. A push when ZYME files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ZYME, by share count.
- Ask anything. An AI agent that reads every ZYME filing and answers with sources.
ZYME alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hollywood Mark | A | Jul 6, 2026 | 939 | $22.22 |
| Schneider Paul R | A | May 13, 2026 | 178,000 | - |
| Schneider Paul R | A | May 13, 2026 | 119,000 | - |
| Schayowitz Adam | A | Apr 9, 2026 | 76,000 | - |
| Schayowitz Adam | A | Apr 9, 2026 | 70,000 | - |
| Platshon Scott | A | Apr 9, 2026 | 47,000 | - |
| Schayowitz Adam | A | Apr 9, 2026 | 47,000 | - |
| Platshon Scott | A | Apr 9, 2026 | 70,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $76.3M | $106.0M |
| Operating Income | - | -$137.1M | -$92.5M |
| Net Income | -$118.7M | -$122.7M | -$81.1M |
| Op. Margin | - | -179.7% | -87.3% |
| Net Margin | - | -160.8% | -76.6% |
| Balance Sheet | |||
| Total Assets | $580.9M | $463.1M | $346.5M |
| Equity | - | $338.8M | $268.5M |
| ROE | - | -36.2% | -30.2% |
| Per Share | |||
| EPS | $-1.72 | $-1.62 | $-1.08 |
| Cash Flow | |||
| Operating CF | - | -$110.0M | -$33.0M |
| CapEx | $2.5M | $2.0M | $1.5M |
Source: XBRL data in Zymeworks Inc. (ZYME)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ZYME share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $385.2M |
| Q1 2026 | 27 | $396.1M |
| Q4 2025 | 25 | $405.3M |
| Q3 2025 | 27 | $306.5M |
| Q2 2025 | 25 | $223.5M |
| Q1 2025 | 23 | $139.1M |
| Q4 2024 | 18 | $95.2M |
| Q3 2024 | 14 | $43.0M |
- State Street Corp+76.4K (+8%)
- FMR LLC (Fidelity)+35.4K (+5%)
- Wells Fargo & Co+27.6K (+15%)
- AQR Capital Management+20.6K (+23%)
- Citigroup+17.1K (+15%)
- BlackRock−302.9K (-7%)
- Morgan Stanley−249.3K (-10%)
- Citadel Advisors LLC−235.9K (-21%)
- Vanguard Capital Management LLC−146.6K (-9%)
- Dimensional Fund Advisors−144.2K (-13%)
- Two Sigma Investments+71.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ZYME filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | May 15, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 15, 2026 | - | - | |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Apr 7, 2026 | - | - | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
| 10-K | Mar 2, 2026 | Dec 31, 2025 | Analysis | |
| 4 | Jan 13, 2026 | - | - | |
| 4 | Jan 13, 2026 | - | - | |
| 4 | Jan 12, 2026 | - | - | |
| 8-K | Jan 12, 2026 | - | - | |
| 4 | Jan 12, 2026 | - | - | |
| 4 | Jan 12, 2026 | - | - | |
| 4 | Jan 12, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ZYME SEC filings: frequently asked questions
Which institutions hold ZYME stock?
As of June 30, 2026, the largest Zymeworks Inc. (ZYME) holders among the 13F filers tracked by SignalX were BlackRock ($111.1 million), Morgan Stanley ($58.3 million), Vanguard Capital Management LLC ($40.8 million), State Street Corp ($28.4 million), Dimensional Fund Advisors ($26.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ZYME's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Zymeworks Inc. (ZYME) reported revenue of $106.0 million (up 38.9% from FY2024) and a net loss of $81.1 million. Diluted EPS was -$1.08. The figures come from the XBRL data in the 10-K.
What are the main risks in ZYME's latest 10-K?
In the 10-K filed March 2, 2026, Zymeworks Inc. (ZYME) flagged: Regulatory risk: BIOSECURE Act may restrict U.S. government contracts to companies using equipment/services from certain Chinese biotech firms, affecting partnerships and operations. Geopolitical risk: Early-stage clinical supplies sourced from China exposed to ongoing U.S.-China trade tensions and tariffs, risking supply chain disruptions. (AI summary of the Risk Factors section.)
What did ZYME report in its latest 8-K?
Zymeworks Inc. (ZYME) filed an 8-K on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 7.01 (Regulation FD Disclosure). Material agreement relates to a Note Purchase Agreement and Guaranty and Security Agreement.
What are the latest ZYME SEC filings?
Zymeworks Inc. (ZYME) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on July 6, 2026.
What is ZYME's SEC CIK number?
Zymeworks Inc. (ZYME)'s SEC Central Index Key (CIK) is 1937653. EDGAR lists every ZYME filing under that number.
Ask anything about ZYME
The research agent reads ZYME's filings, financials, insider trades and 13F holders, then answers with sources.